NSE filing, NSE: MADHAVBAUG. Summary written from the filing by ALFA Finder's alert engine.
Vaidya Sane Ayurved Laboratories Ltd: key numbers
- Share price
- ₹140.25
- Market cap
- ₹147.4 Cr
- Revenue (annual)
- ₹106.9 Cr
- Net profit (annual)
- ₹8.99 Cr
- P/E (TTM)
- 16.4×Sector 35.3×
- Promoter holding
- 66.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaidya Sane Ayurved Laboratories Ltd
All →Vaidya Sane Ayurved Laboratories H1 FY27 Results: Net Loss of ₹0.2 Cr
Vaidya Sane Ayurved Laboratories Ltd reported revenue from operations of ₹58.7 Cr (+17.6% YoY) and a net loss of ₹0.2 Cr for H1 FY27.
- Key figure
- Net loss ₹0.2 Cr
Vaidya Sane Ayurved Laboratories Other Announcement
The Company has filed an undertaking confirming that Corporate Governance provisions under Regulation 27 of SEBI (LODR) are not applicable for the current quarter.
Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories held its 27th AGM on September 30, 2026. Shareholders considered the adoption of financial results, auditor re-appointments, and approval of ESOP 2026.
Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
Vaidya Sane Ayurved Laboratories Board Meeting Outcome
The company's board approved the 27th AGM details, director/auditor re-appointments, an increase in MD remuneration, and the introduction of the 'VSALL - ESOP 2026' scheme.
Vaidya Sane Ayurved Laboratories Other Announcement
Vaidya Sane Ayurved Laboratories filed a statement of deviation or variation in fund utilization pursuant to Regulation 32(1) for the quarter ended June 30, 2026.
Other product launch announcements
All →Bharat Forge Product Launch
Bharat Forge's defence subsidiary KSSL unveiled the 120mm Rapid Attack Mortar System for Indian Armed Forces and international customers. No order value or contract was announced.
Lupin Product Launch
Lupin announced the European launch of its biosimilar Ranibizumab (Ranluspec) via commercial partner Sandoz. The launch covers Europe excluding Germany following European Commission approval.
LTM Product Launch
LTM publishes AI-QEM, its Quantum Error Mitigation tool, in IBM's Quantum Functions Catalog, becoming the first global systems integrator to do so.
Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.